Continuous Positive Airway Pressure for the Treatment of Supine Hypertension and Orthostatic Hypotension in Autonomic Failure.
Luis E Okamoto, Jorge E Celedonio, Emily C Smith...
https://pubmed.ncbi.nlm.nih.gov/36601916/Actively Recruiting
Led by Vanderbilt University Medical Center · Updated on 2025-11-06
12
Participants Needed
1
Research Sites
13 weeks
Total Duration
Supine hypertension, a condition affecting at least half of patients with primary autonomic failure, can be severe and complicates treatment for orthostatic hypotension. This research aims to find out whether using continuous positive airway pressure CPAP can lower blood pressure in patients with autonomic failure who have supine hypertension. The mechanisms causing this condition are not fully understood, and current drugs may worsen the problem or cause organ damage. The study is sponsored by Vanderbilt University Medical Center and is interventional in design. The study evaluates two treatment approaches one group receives placebo pills, patches, or sham CPAP, while the other group uses CPAP during the night. An acute CPAP trial determines the appropriate pressure level, which is then applied overnight starting from 800 PM. The CPAP device delivers air pressure through a mask to keep airways open, with pressure levels tested sequentially at 0, 4, 8, 12, and 16 cm H2O for 1 to 20 minutes each to assess blood pressure response and tolerability. Participants will be monitored for changes in their supine systolic blood pressure over a 12-hour period, which is the primary outcome measure. Secondary measures include urinary volume over 12 hours. The study involves randomized allocation without masking or blinding. Participants undergo blood pressure assessments during the acute CPAP trial and may continue with CPAP overnight if tolerated. The trial excludes healthy volunteers and runs until December 2026, with participants ranging from 18 to 85 years old.
CONDITIONS
Treatment of Supine Hypertension in Autonomic Failure (CPAP)
B
Bonnie K Black, RN
L
Luis E Okamoto, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Vanderbilt University Medical Center
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | CPAP (continuous positive airway pressure) | Placebo pill or patch or sham CPAP |
|---|---|---|
| What it is | Continuous positive airway pressure (CPAP) applies sustained air pressure overnight to help manage supine hypertension in people with autonomic failure. | Placebo pill or patch or sham CPAP is given as a control condition to compare effects against CPAP. |
| Role in the trial | Active intervention tested for its ability to lower supine blood pressure overnight. | Serves as the comparator for evaluating CPAP efficacy in the same participants. |
| Primary use | Intended to lower supine blood pressure and reduce nighttime hypertension symptoms for people with autonomic failure. | Used as a control to compare with CPAP and measure changes in supine blood pressure. |
| How it is given or performed | CPAP device is applied overnight starting at 8:00 pm, with pressure levels set individually during an acute trial. | Placebo pill or patch is given as a single dose; sham CPAP delivers no pressure to simulate device use. |
| Evidence status | External published evidence supports CPAP as a potential therapy to lower supine hypertension in autonomic failure, but more clinical studies are needed to confirm benefit and long-term effects. | Used as a control, placebo/sham has no expected effect on supine hypertension outcomes. |
| Important limitations | Study population is small; actual patient benefit, tolerability, device adherence, and long-term safety are not fully established. Overnight CPAP use may not suit all patients. | Does not address the underlying cause of supine hypertension and provides no therapeutic benefit. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 hours per treatment session
Participants receive continuous positive airway pressure (CPAP) during the night or placebo pill, patch, or sham CPAP in a randomized crossover design.
1 baseline visit and 1 follow-up visit per treatment period
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Luis E Okamoto, Jorge E Celedonio, Emily C Smith...
https://pubmed.ncbi.nlm.nih.gov/36601916/Vanderbilt University Medical Center
Lead Sponsor